These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33611431)

  • 1. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
    Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
    Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS; Ren C; Li SS; Fong WP; Wu XJ; Xiao J; Li BK; Zheng Y; Ding PR; Chen G; Qiu MZ; Wang ZQ; Wang FH; Luo HY; Wang F; Wang XZ; Wang LY; Xie DJ; Chen T; Li LR; Lu ZH; Zhai XH; Liu TS; Yuan Y; Chen JQ; Tan Q; Pan ZZ; Wan DS; Zhang R; Yuan YF; Xu RH; Li YH
    PLoS Med; 2024 May; 21(5):e1004389. PubMed ID: 38728364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
    J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
    Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
    Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
    Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
    Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
    BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    Pernot S; Pellerin O; Artru P; Montérymard C; Smith D; Raoul JL; De La Fouchardière C; Dahan L; Guimbaud R; Sefrioui D; Jouve JL; Lepage C; Tougeron D; Taieb J;
    Br J Cancer; 2020 Aug; 123(4):518-524. PubMed ID: 32507854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
    BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Ruers T; Van Coevorden F; Punt CJ; Pierie JE; Borel-Rinkes I; Ledermann JA; Poston G; Bechstein W; Lentz MA; Mauer M; Folprecht G; Van Cutsem E; Ducreux M; Nordlinger B; ; ; ;
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer.
    You YT; Changchien CR; Huang JS; Ng KK
    Int J Colorectal Dis; 2006 Jan; 21(1):33-7. PubMed ID: 15942741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Hepatic Artery-Based Therapies and Systemic Multiagent Chemotherapy in Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.
    Sugumar K; Stitzel H; Wu V; Bajor D; Chakrabarti S; Conces M; Henke L; Lumish M; Mahipal A; Mohamed A; Winter JM; Hardacre JM; Ammori JB; Selfridge JE; Ocuin LM
    Ann Surg Oncol; 2024 Jul; 31(7):4413-4426. PubMed ID: 38502296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line systemic therapy for metastatic colorectal cancer.
    Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
    Pernot S; Artru P; Mithieux F; Marsot J; Watkin E; Pellerin O; Lledo G; Chalabreysse P; Desramé J; Taieb J
    Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e73-7. PubMed ID: 26141343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.